ProMetic Life Sciences Inc. (TSE:PLI) has been given a consensus recommendation of “Buy” by the six research firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is C$4.46.

A number of research firms recently commented on PLI. Royal Bank Of Canada dropped their price objective on ProMetic Life Sciences from C$4.25 to C$4.00 and set an “outperform” rating on the stock in a report on Monday, April 3rd. Scotiabank restated an “outperform” rating and issued a C$4.75 price objective on shares of ProMetic Life Sciences in a report on Wednesday, April 19th. TD Securities set a C$4.50 price objective on ProMetic Life Sciences and gave the stock a “speculative buy” rating in a report on Monday, April 3rd. Finally, Canaccord Genuity dropped their price objective on ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating on the stock in a report on Monday, June 19th.

ProMetic Life Sciences (PLI) traded down 4.32% during midday trading on Tuesday, reaching $1.55. 1,010,790 shares of the company’s stock traded hands. ProMetic Life Sciences has a 52 week low of $1.47 and a 52 week high of $3.24. The stock’s market capitalization is $1.04 billion. The company’s 50-day moving average price is $1.95 and its 200 day moving average price is $2.11.

In other ProMetic Life Sciences news, Director Louise Ménard sold 82,202 shares of the stock in a transaction that occurred on Monday, July 10th. The stock was sold at an average price of C$1.60, for a total transaction of C$131,523.20. In the last quarter, insiders have acquired 38,424 shares of company stock worth $77,709.

TRADEMARK VIOLATION WARNING: “ProMetic Life Sciences Inc. (PLI) Given Consensus Rating of “Buy” by Analysts” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/07/11/prometic-life-sciences-inc-pli-given-consensus-rating-of-buy-by-analysts.html.

About ProMetic Life Sciences

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.